Teladoc Inc (NYSE:TDOC) has been assigned a consensus rating of “Buy” from the eighteen analysts that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $39.25.

Several research analysts recently weighed in on the stock. Cowen restated an “outperform” rating and set a $39.00 price target on shares of Teladoc in a research report on Saturday, September 30th. Piper Jaffray Companies restated a “buy” rating and set a $42.00 price target on shares of Teladoc in a research report on Friday, September 29th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $31.00 price objective on shares of Teladoc in a research note on Tuesday, September 26th. ValuEngine raised shares of Teladoc from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Finally, Zacks Investment Research raised shares of Teladoc from a “sell” rating to a “hold” rating in a research note on Thursday, September 21st.

Teladoc (NYSE:TDOC) traded down $1.45 on Tuesday, hitting $36.05. 2,553,800 shares of the company traded hands, compared to its average volume of 1,245,980. Teladoc has a 52-week low of $15.65 and a 52-week high of $38.40. The company has a debt-to-equity ratio of 0.83, a quick ratio of 5.08 and a current ratio of 5.08. The firm has a market cap of $2,180.00 and a P/E ratio of -24.86.

Teladoc (NYSE:TDOC) last released its quarterly earnings results on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.25). Teladoc had a negative return on equity of 29.70% and a negative net margin of 45.64%. The company had revenue of $68.70 million for the quarter, compared to analyst estimates of $67.53 million. During the same quarter last year, the company earned ($0.33) EPS. The firm’s revenue for the quarter was up 112.0% on a year-over-year basis. sell-side analysts expect that Teladoc will post -1.56 earnings per share for the current year.

In related news, CEO Jason N. Gorevic sold 20,000 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $32.10, for a total transaction of $642,000.00. Following the completion of the transaction, the chief executive officer now owns 838,261 shares of the company’s stock, valued at approximately $26,908,178.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Mark Hirschhorn sold 25,000 shares of the stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $32.37, for a total transaction of $809,250.00. Following the transaction, the chief financial officer now directly owns 20,887 shares of the company’s stock, valued at approximately $676,112.19. The disclosure for this sale can be found here. In the last three months, insiders sold 210,000 shares of company stock valued at $6,889,350. Corporate insiders own 4.47% of the company’s stock.

Several large investors have recently bought and sold shares of TDOC. Schwab Charles Investment Management Inc. boosted its position in shares of Teladoc by 34.5% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 198,264 shares of the health services provider’s stock worth $6,880,000 after purchasing an additional 50,899 shares during the period. Rhumbline Advisers lifted its holdings in Teladoc by 141.6% during the 2nd quarter. Rhumbline Advisers now owns 59,930 shares of the health services provider’s stock worth $2,080,000 after buying an additional 35,120 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Teladoc by 22.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 279,392 shares of the health services provider’s stock worth $9,695,000 after buying an additional 52,032 shares in the last quarter. Legal & General Group Plc lifted its holdings in Teladoc by 117.8% during the 2nd quarter. Legal & General Group Plc now owns 13,364 shares of the health services provider’s stock worth $466,000 after buying an additional 7,227 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its holdings in Teladoc by 846.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 6,276 shares of the health services provider’s stock worth $218,000 after buying an additional 5,613 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: “Teladoc Inc (TDOC) Given Consensus Recommendation of “Buy” by Brokerages” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/teladoc-inc-tdoc-given-consensus-recommendation-of-buy-by-brokerages/1799882.html.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Analyst Recommendations for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.